<DOC>
	<DOCNO>NCT00713648</DOCNO>
	<brief_summary>The trial conduct Europe , North America Asia . The aim trial evaluate catridecacog ( recombinant factor XIII ( rFXIII ) ) treatment patient inherit FXIII deficiency . It expect recombinant FXIII use prevention bleed episode .</brief_summary>
	<brief_title>Evaluation Recombinant Factor XIII Prevention Bleeding Patients With FXIII Inherited Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Diagnosis congenital FXIII Asubunit deficiency ( confirm genotyping screen visit ) Treatment regular FXIII replacement therapy initiate least 6 month prior screen one following : documented history least one 1 treatmentrequiring bleeding episode prior initiation regular replacement therapy document family history FXIII congenital deficiency ( subject regular replacement therapy prior screen ) Documented history least two 2 bleed episode require treatment FXIII contain blood product within last 12 month prior screen ( subject receive ondemand treatment prior screen ) Known neutralize antibody ( inhibitor ) towards FXIII Any known congenital acquire coagulation disorder congenital FXIII deficiency Documented history least 2 treatmentrequiring bleed episode per year previous regular replacement therapy FXIII contain blood product ( fresh frozen plasma ( FFP ) , plasmaderived FXIII ( pd FXIII ) cryoprecipitate ) Known suspect allergy trial product ( ) relate product Planned major surgery trial period . Catheter , port dental extraction count surgery exclude subject Renal insufficiency define current dialysis therapy Any history confirm venous arterial thromboembolic event</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>